RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital
The newly combined company will further advance novel compounds that both activate the natural immune activation and demonstrate antiviral activity.
- The newly combined company will further advance novel compounds that both activate the natural immune activation and demonstrate antiviral activity.
- F-Prime Capital has invested in the new company as part of the Subintro acquisition.
- With the strategic Subintro acquisition, RIGImmune will target intranasal delivery to amplify the mucosal innate immune and antiviral responses.
- Subintro will become a wholly owned subsidiary of RIGImmune and Nihal Sinha, Ph.D. from F-Prime Capital will join the board of RIGImmune.